ESPERION Appoints Sheldon Koenig as Chief Operating Officer
December 15, 2020 07:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Sheldon Koenig, a proven leader in the cardiovascular market, as chief operating...
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
November 10, 2020 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal...
NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia
October 07, 2020 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced results of pooled data from two of the company’s Phase 3 trials were presented at the virtual 88th Annual...
Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement
June 22, 2020 07:00 ET
|
Esperion Therapeutics, Inc.
Esperion to Receive $150 Million Milestone Payment in June Esperion Completes Transfer of Marketing Authorization Approvals (MAAs) for NILEMDO™ (bempedoic acid) and NUSTENDI™ (bempedoic acid and...
Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions
June 14, 2020 09:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 14, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analysis from four Phase 3 clinical studies of NEXLETOL were presented at the American...
Esperion to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
June 08, 2020 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 08, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering
June 04, 2020 07:00 ET
|
Esperion Therapeutics, Inc.
– First-Ever Non-Statin Combination Medicine, Providing 38 Percent Mean LDL-C Lowering – – Esperion Aims to Set New Industry Standard by Pricing NEXLIZET for Patient Affordability and Access with...
Esperion to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference 2020
May 27, 2020 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 15, 2020 18:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 15, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on May 15, 2020, the Compensation Committee of Esperion’s Board of Directors granted 88,902...
Esperion to Participate in Fireside Chat at the BofA Securities 2020 Healthcare Conference
May 07, 2020 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside...